Created at	Source	Raw Value	Validated value
March 27, 2022, 4 p.m.	usa	Geometric Mean Titer (GMT) of SARS-CoV-2 Specific Neutralizing Antibody (nAb) for Participants in Part A;GMT of SARS-CoV-2 Specific nAB for Participants in Part B;Number of Participants with AEs Leading to Withdrawal;Number of Participants with AEs of Special Interest (AESIs);Number of Participants with Biopsy-Proven Organ Rejection;Number of Participants with Medically-Attended AEs (MAAEs);Number of Participants with Serious AEs (SAEs);Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs) in Part A;Number of Participants with Solicited Local and Systemic ARs in Part B;Number of Participants with Unsolicited Adverse Events (AEs) in Part A;Number of Participants with Unsolicited AEs in Part B	Geometric Mean Titer (GMT) of SARS-CoV-2 Specific Neutralizing Antibody (nAb) for Participants in Part A;GMT of SARS-CoV-2 Specific nAB for Participants in Part B;Number of Participants with AEs Leading to Withdrawal;Number of Participants with AEs of Special Interest (AESIs);Number of Participants with Biopsy-Proven Organ Rejection;Number of Participants with Medically-Attended AEs (MAAEs);Number of Participants with Serious AEs (SAEs);Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs) in Part A;Number of Participants with Solicited Local and Systemic ARs in Part B;Number of Participants with Unsolicited Adverse Events (AEs) in Part A;Number of Participants with Unsolicited AEs in Part B
Oct. 26, 2021, 11 a.m.	usa	Geometric Mean Titer (GMT) of SARS-CoV-2 Specific Neutralizing Antibody (nAb) for Participants;Number of Participants with AEs Leading to Withdrawal;Number of Participants with AEs of Special Interest (AESIs);Number of Participants with Biopsy-Proven Organ Rejection;Number of Participants with Medically-Attended AEs (MAAEs);Number of Participants with Serious AEs (SAEs);Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs);Number of Participants with Unsolicited Adverse Events (AEs)	Geometric Mean Titer (GMT) of SARS-CoV-2 Specific Neutralizing Antibody (nAb) for Participants;Number of Participants with AEs Leading to Withdrawal;Number of Participants with AEs of Special Interest (AESIs);Number of Participants with Biopsy-Proven Organ Rejection;Number of Participants with Medically-Attended AEs (MAAEs);Number of Participants with Serious AEs (SAEs);Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs);Number of Participants with Unsolicited Adverse Events (AEs)
July 20, 2021, 4 p.m.	usa	Geometric Mean Titer (GMT) of SARS-CoV-2 Specific Neutralizing Antibody (nAb);Number of Participants with Adverse Events (AEs) Leading to Withdrawal;Number of Participants with Adverse Events of Special Interest (AESIs);Number of Participants with Biopsy-proven Organ Rejection;Number of Participants with Medically-Attended AEs (MAAEs);Number of Participants with Serious Adverse Events (SAEs);Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs);Number of Participants with Unsolicited Adverse Events (AEs)	Geometric Mean Titer (GMT) of SARS-CoV-2 Specific Neutralizing Antibody (nAb);Number of Participants with Adverse Events (AEs) Leading to Withdrawal;Number of Participants with Adverse Events of Special Interest (AESIs);Number of Participants with Biopsy-proven Organ Rejection;Number of Participants with Medically-Attended AEs (MAAEs);Number of Participants with Serious Adverse Events (SAEs);Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs);Number of Participants with Unsolicited Adverse Events (AEs)
April 28, 2021, 12:31 a.m.	usa	Geometric Mean Titer (GMT) of SARS-CoV-2 Specific Neutralizing Antibody (nAb);Number of Participants with Adverse Events (AEs) Leading to Withdrawal;Number of Participants with Biopsy-proven Organ Rejection;Number of Participants with Medically-Attended AEs (MAAEs);Number of Participants with Serious Adverse Events (SAEs);Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs);Number of Participants with Unsolicited Adverse Events (AEs)	Geometric Mean Titer (GMT) of SARS-CoV-2 Specific Neutralizing Antibody (nAb);Number of Participants with Adverse Events (AEs) Leading to Withdrawal;Number of Participants with Biopsy-proven Organ Rejection;Number of Participants with Medically-Attended AEs (MAAEs);Number of Participants with Serious Adverse Events (SAEs);Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs);Number of Participants with Unsolicited Adverse Events (AEs)